文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

阿托伐他汀与阿司匹林作为SARS-CoV-2感染患者辅助治疗:随机对照试验方案的结构化摘要

Atorvastatin and Aspirin as Adjuvant Therapy in Patients with SARS-CoV-2 Infection: A structured summary of a study protocol for a randomised controlled trial.
PubMed 文献 · Trials · 2020-10-30

该试验为单中心、前瞻性、四臂平行、开放标签随机对照试验,纳入年龄≥40岁且<75岁、需住院的RT-PCR确诊SARS-CoV-2感染患者,比较阿托伐他汀和/或阿司匹林联合常规治疗与单纯常规治疗对临床恶化的影响及安全性。主要结局为WHO临床改善序数评分≥6的临床恶化,计划每组前200例(共800例)后基于 interim 分析确定最终样本量。

要点

  • 纳入WHO序数评分3-5的住院COVID-19患者,排除危重症及肝病、肌病、出血风险者。
  • 阿托伐他汀40mg每日一次或阿司匹林75mg每日一次,用10天或至出院。
  • 主要结局为进展至WHO序数评分≥6(插管、机械通气、升压药、肾脏替代、ECMO或死亡)。

核心结论

  • 该方案旨在评估阿托伐他汀和/或阿司匹林辅助治疗能否减少住院SARS-CoV-2感染患者的临床恶化,并评价其安全性。

研究设计与样本

  • 单中心、前瞻性、四臂平行设计、开放标签随机对照试验,在印度哈里亚纳邦Jhajjar的国家癌症研究所(NCI)进行。
  • 纳入年龄≥40岁且<75岁、RT-PCR确诊SARS-CoV-2感染、需住院且WHO临床改善序数评分3至5的患者。
  • 采用计算机生成的置换区组随机化(混合区组大小),按1:1:1:1比例分为A组(阿托伐他汀+常规治疗)、B组(阿司匹林+常规治疗)、C组(阿司匹林+阿托伐他汀+常规治疗)、D组(仅常规治疗)。
  • 因无现有研究评估阿司匹林和阿托伐他汀在COVID-19患者中的作用,未进行正式样本量计算;计划每组前200例(共800例)后进行 interim 分析以确定最终样本量。

关键数值与推荐

  • 阿托伐他汀用法:40 mg口服片,每日一次,用10天或至出院(以较早者为准)。
  • 阿司匹林用法:75 mg每日一次,用10天或至出院(以较早者为准)。
  • 主要结局:临床恶化,定义为进展至WHO临床改善序数评分≥6(气管插管、无创机械通气、升压药、肾脏替代治疗、ECMO需求或死亡)。
  • 次要结局:从研究入组至第5天或症状出现后第7天(以较晚者为准)血清炎症标志物(C反应蛋白和白细胞介素-6)、肌钙蛋白I和肌酸磷酸激酶(CPK)的变化。
  • 其他临床结局:进展至急性呼吸窘迫综合征(ARDS)、休克、ICU入住、ICU入住时长、住院时长及院内死亡;不良药物反应包括肌痛、肌病、横纹肌溶解、肝毒性和出血。

临床怎么用

  • 该方案为住院COVID-19患者使用阿托伐他汀和/或阿司匹林辅助治疗提供了随机对照试验框架,结果将指导临床决策。

局限性

  • 单中心、开放标签设计可能引入偏倚。
  • 未进行正式样本量计算,最终样本量基于 interim 分析确定。
  • 研究期间为6个月, recruitment 时间为2020年7月28日至2021年1月27日。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the impact of adding statin (atorvastatin) and/or aspirin on clinical deterioration in patients infected with SARS-CoV-2 who require hospitalisation. The safety of these drugs in COVID-19 patients will also be evaluated. TRIAL DESIGN: This is a single-centre, prospective, four-arm parallel design, open-label, randomized control trial. PARTICIPANTS: The study will be conducted at National Cancer Institute (NCI), Jhajjar, Haryana, which is a part of All India Institute of Medical Sciences (AIIMS), New Delhi, and has been converted into a dedicated COVID-19 management centre since the outbreak of the pandemic. All RT-PCR confirmed cases of SARS-CoV-2 infection with age ≥ 40 years and < 75 years requiring hospital admission (patients with WHO clinical improvement ordinal score 3 to 5) will be included in the trial. Written informed consent will be taken for all recruited patients. Patients with a critical illness (WHO clinical improvement ordinal score > 5), documented significant liver disease/dysfunction (aspartate transaminase [AST] / alanine aminotransferase [ALT] > 240), myopathy and rhabdomyolysis (creatine phosphokinase [CPK] > 5x normal), allergy or intolerance to statins or aspirin, prior statin or aspirin use within 30 days, history of active gastrointestinal bleeding in past three months, coagulopathy, thrombocytopenia (platelet count < 100000/ dl), pregnancy, active breastfeeding, or inability to take oral or nasogastric medications will be excluded. Patients refusing to give written consent and taking drugs that are known to have a significant drug interaction with statin or aspirin [including cyclosporine, HIV protease inhibitors, hepatitis C protease inhibitor, telaprevir, fibric acid derivatives (gemfibrozil), niacin, azole antifungals (itraconazole, ketoconazole), clarithromycin and colchicine] will also be excluded from the trial. INTERVENTION AND COMPARATOR: In this study, the benefit and safety of atorvastatin (statin) and/or aspirin as adjuvant therapy will be compared with the control group receiving usual care for management of COVID-19. Atorvastatin will be prescribed as 40 mg oral tablets once daily for ten days or until discharge, whichever is earlier. The dose of aspirin will be 75 mg once daily for ten days or until discharge, whichever is earlier. All other therapies will be administered according to the institute's COVID-19 treatment protocol and the treating physician's clinical judgment. MAIN OUTCOMES: All study participants will be prospectively followed up for ten days or until hospital discharge, whichever is longer for outcomes. The primary outcome will be clinical deterioration characterized by progression to WHO clinical improvement ordinal score ≥ 6 (i.e., endotracheal intubation, non-invasive mechanical ventilation, pressor agents, renal replacement therapy, ECMO requirement, and mortality). The secondary outcomes will be change in serum inflammatory markers (C-reactive protein and Interleukin-6), Troponin I, and creatine phosphokinase (CPK) from time zero to 5th day of study enrolment or 7th day after symptom onset, whichever is later. Other clinical outcomes that will be assessed include progression to Acute Respiratory Distress Syndrome (ARDS), shock, ICU admission, length of ICU admission, length of hospital admission, and in-hospital mortality. Adverse drug effects like myalgia, myopathy, rhabdomyolysis, hepatotoxicity, and bleeding will also be examined in the trial to assess the safety of the interventions. RANDOMISATION: The study will use a four-arm parallel-group design. A computer-generated permuted block randomization with mixed block size will be used to randomize the participants in a 1:1:1:1 ratio to group A (atorvastatin with conventional therapy), group B (aspirin with conventional therapy), group C (aspirin + atorvastatin with conventional therapy), and group D (control; only conventional therapy). BLINDING (MASKING): The study will be an open-label trial. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): As there is no existing study that has evaluated the role of aspirin and atorvastatin in COVID-19 patients, formal sample size calculation has not been done. Patients satisfying the inclusion and exclusion criteria will be recruited during six months of study period. Once the first 200 patients are included in each arm (i.e., total 800 patients), the final sample size calculation will be done on the basis of the interim analysis of the collected data. TRIAL STATUS: The institutional ethical committee has approved the study protocol (Protocol version 3.0 [June 2020]). Participant recruitment starting date: 28th July 2020 Participant recruitment ending date: 27th January 2021 Trial duration: 6 months TRIAL REGISTRATION: The trial has been prospectively registered in Clinical Trial Registry - India (ICMR- NIMS): Reference no. CTRI/2020/07/026791 (registered on 25 July 2020)]. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Ghati N, Roy A, Bhatnagar S, et al. Atorvastatin and Aspirin as Adjuvant Therapy in Patients with SARS-CoV-2 Infection: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020. PMID: 33126910. doi:10.1186/s13063-020-04840-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。